Quest Diagnostics Inc vs Roundhill NVDA WeeklyPay ETF — how do they compare? Quest Diagnostics Inc trades at $230.97 (market cap $25.48B), while Roundhill NVDA WeeklyPay ETF trades at $37.11 (market cap $119.10M). The key difference: Quest Diagnostics Inc is far larger — about 213.9× Roundhill NVDA WeeklyPay ETF's market cap, and Quest Diagnostics Inc pays a 1.49% dividend while Roundhill NVDA WeeklyPay ETF pays none. Which is the better fit depends on your goals — on Pluang, investors hold Quest Diagnostics Inc for 56 Days and Roundhill NVDA WeeklyPay ETF for 50 Days on average.
| DGX | NVDW | |
|---|---|---|
Market Cap | $25.48B | $119.10M |
Volume | 941,866 | 44,838 |
Sector | Health | Income / Options Overlay |
52-Week High | $247.45 | $52.33 |
52-Week Low | $173.49 | $31.88 |
Typical Hold Time | 56 Days | 50 Days |
Enterprise Value | $31.23B | — |
Dividend Yield | 1.49% | — |
Signals from Pluang's Aura AI — not financial advice
Quest Diagnostics (DGX) trades at $230.81, up 1.68% today, with a bullish earnings trend after beating EPS estimates for three consecutive quarters. The stock shows a mixed technical picture with a bearish overall signal but trades near key support at $228. Revenue growth accelerated to $11.04B in 2025, and the company maintains solid profitability with a 9.19% net income margin. Recent news highlights growth in consumer testing and a partnership with Apple Health, though Medicare reimbursement cuts pose a headwind.
The outlook is cautiously optimistic, supported by strong fundamentals and a consensus price target of $250 offering 8% upside. Key opportunities include demand for advanced diagnostics and AI adoption, while risks center on regulatory pressure and rising debt levels. Analyst sentiment is mixed with a slight hold bias, reflecting balanced growth prospects against near-term challenges.
NVDW trades at $37.11, down 4.11% today, with technical indicators showing a bullish trend from moving averages but neutral oscillators. The ETF provides weekly dividend income tied to Nvidia's performance with 120% leveraged exposure. Recent Nvidia earnings beat expectations, supporting the AI theme's momentum, though the fund carries elevated risk due to leverage and NAV volatility during Nvidia downturns.
The outlook remains tied to Nvidia's AI-driven growth, offering high-yield income potential but with significant volatility risk. Investors face exposure to Nvidia's stock performance amplified by leverage, making the fund suitable for risk-tolerant income seekers but vulnerable to sharp corrections in the underlying asset.
Trailing returns across standard periods
What Pluang investors did over the last 30 days
No sentiment data available yet.
Quest Diagnostics is a leading independent provider of diagnostic testing, information, and services in the U.S. The company generates over 95% of its revenue through clinical testing, anatomic pathology, esoteric testing, and substance abuse testing with specimens collected at its national network of roughly 2,300 patient service centers, as well as multiple doctors offices and hospitals. The firm also runs a much smaller diagnostic solutions segment that provides clinical trials testing, risk assessment services, and information technology solutions.
Read more on DGX →NVDW is an actively managed ETF that seeks to provide weekly distributions and returns equal to 1.2 times (120%) the calendar week performance of Nvidia (NVDA) common shares. It combines modest leverage with a high-frequency payout schedule, designed for investors who want amplified exposure to Nvidia alongside a consistent weekly income stream.
Read more on NVDW →